利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.037 秒)

    Compositions for treatment or prevention of bioterrorism
    1.
    发明授权
    Compositions for treatment or prevention of bioterrorism 有权
    用于治疗或预防生物恐怖主义的组成部分

    公开(公告)号：US06991779B2

    公开(公告)日：2006-01-31

    申请号：US10347932

    申请日：2003-01-17

    申请人： Solomon S. Steiner ,  Cohava Gelber ,  Robert S. Feldstein ,  Roderike Pohl

    发明人： Solomon S. Steiner ,  Cohava Gelber ,  Robert S. Feldstein ,  Roderike Pohl

    IPC分类号： A61K9/12 ,  A61K9/72

    CPC分类号： A61K9/0075 ,  A61K9/1617 ,  A61K9/1641 ,  A61K31/46 ,  A61K31/495 ,  A61K39/00 ,  A61K39/07 ,  A61K2039/505 ,  A61K2039/55555 ,  C07K16/12

    摘要： Compositions containing biologically active molecules encapsulated in self-assembling, diketopiperazine microspheres (TECHNOSPHEREs™) and methods for making and administering such compositions are described herein. The compositions can be used to immunize individuals against agents of biological warfare. The biologically active molecules include atropine, antibodies, antigens, and antibiotics. The compositions can be placed in an inhalation device for self-administration. Pulmonary delivery of TECHNOSPHERE™ encapsulated atropine, antibodies, vaccines, and antibiotics provides an accelerated onset of immunity to the targeted disease. Furthermore, the TECHNOSPHERE™ encapsulated atropine, antibodies, vaccines, and antibiotics are stable formulations, suitable for stockpiling, rapid dissemination and mass treatment.

    摘要翻译： 包含自组装，二酮哌嗪微球体（TECHNOSPHERE TM）中的生物活性分子的组合物以及制备和施用此类组合物的方法在本文中描述。 组合物可用于免疫个体对生物战的药剂。 生物活性分子包括阿托品，抗体，抗原和抗生素。 组合物可以放置在用于自我给药的吸入装置中。 包含阿托品，抗体，疫苗和抗生素的TECHNOSPHERE TM的肺转运提供了对目标疾病免疫的加速发作。 此外，TECHNOSPHERE（TM）包裹阿托品，抗体，疫苗和抗生素是稳定的配方，适合储存，快速传播和大量治疗。

    Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
    7.
    发明授权
    Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof 失效
    卵巢癌细胞和骨髓瘤细胞表面糖蛋白，其抗体及其用途

    公开(公告)号：US07226750B1

    公开(公告)日：2007-06-05

    申请号：US10049608

    申请日：2000-08-08

    申请人： Cohava Gelber

    发明人： Cohava Gelber

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57449 ,  G01N2800/52

    摘要： The present invention is directed to cell surface antigenes found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable of being used for therapeutic, screening, diagnostic and cell purification purposes. A representative and exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to a surface antigen that is expressed on multiple myeloma cells and to a surface antigen that is expressed on ovarian cancer cells. The function of this monoclonal antibody both in vivo and in vitro is demonstrated.

    摘要翻译： 本发明涉及如上所述的由单克隆抗体识别的骨髓瘤细胞和卵巢癌细胞上发现的细胞表面抗原及其抗体结合片段。 本发明的单克隆抗体能够用于治疗，筛选，诊断和细胞纯化目的。 本发明的代表性和示例性的单克隆抗体识别并结合到在多发性骨髓瘤细胞上表达的表面抗原和在卵巢癌细胞上表达的表面抗原共有的表位。 证明了该单克隆抗体在体内和体外的功能。

    Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLS)
    9.
    发明授权
    Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLS) 有权
    用于检测和治疗小细胞肺癌（SCLS）的单克隆抗体和细胞表面抗原

    公开(公告)号：US07687607B2

    公开(公告)日：2010-03-30

    申请号：US12205025

    申请日：2008-09-05

    申请人： Cohava Gelber

    发明人： Cohava Gelber

    IPC分类号： C07K16/30

    CPC分类号： C07K16/3023 ,  A61K2039/505 ,  C07K2317/77 ,  G01N33/57423 ,  G01N33/57438 ,  G01N2800/52

    摘要： The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease. The antibody-recognized SCLC-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing SCLC cells.

    摘要翻译： 本发明提供了新的单克隆抗体及其结合片段，其识别并与小细胞肺癌（SCLC）细胞上发现的细胞表面抗原免疫反应。 该抗体具有肿瘤特异性，可用于治疗，诊断，监测，检测和成像SCLC疾病和患有SCLC疾病的患者。 抗体识别的SCLC特异性表面抗原可以作为检测，诊断，抑制或杀死SCLC细胞的靶标。

    Cell Transport Compositions and Uses Thereof
    10.
    发明申请
    Cell Transport Compositions and Uses Thereof 审中-公开
    细胞运输组合物及其用途

    公开(公告)号：US20090232891A1

    公开(公告)日：2009-09-17

    申请号：US12471260

    申请日：2009-05-22

    申请人： Cohava Gelber ,  Kathleen Rousseau

    发明人： Cohava Gelber ,  Kathleen Rousseau

    IPC分类号： A61K9/10 ,  A61K39/395 ,  A61K38/02

    CPC分类号： A61K9/1617 ,  A61K9/0075 ,  A61K9/1641 ,  A61K9/167 ,  A61K9/1676 ,  A61K38/28 ,  A61K38/38

    摘要： Compositions and methods have been developed for transporting compounds across membranes with little or no toxicity and, when targeted through the appropriate routes of administration (i.e., lung, gastrointestinal (GI) tract), little or no immune stimulation. The compositions can mediate cellular delivery of compounds that would otherwise not enter cells and enhance the intracellular delivery of compounds that would otherwise enter cells inefficiently. The methods are carried out by contacting a proximal face of a lipid bilayer or membrane (e.g. the surface of an intact cell) with a complex containing a compound (e.g., a therapeutic agent) and a diketopiperazine (DKP). DKP and the compound are non-covalently associated with each other or covalently bound to each other.

    摘要翻译： 已经开发了用于将化合物输送到具有很小或没有毒性的膜上的组合物和方法，并且当通过适当的给药途径（即，肺，胃肠道（GI））靶向）时，很少或没有免疫刺激。 组合物可以介导化合物的细胞递送，否则这些化合物将不会进入细胞并且增强否则将无效地进入细胞的化合物的细胞内递送。 所述方法通过使脂质双层或膜（例如完整细胞的表面）的近端与含有化合物（例如治疗剂）和二酮哌嗪（DKP）的复合物接触来进行。 DKP和化合物彼此非共价结合或共价结合。